Where is iqos from

Overview

IQOS is a heated tobacco product developed by Philip Morris International (PMI), a Swiss-American multinational tobacco company founded in 1847. The product represents PMI's strategic shift toward "smoke-free" alternatives, aiming to reduce the harm associated with traditional combustible cigarettes. IQOS was first introduced in Nagoya, Japan in 2014, marking a pivotal moment in the tobacco industry's evolution toward potentially less harmful nicotine delivery systems.

The development of IQOS began in the late 2000s as part of PMI's multi-billion dollar investment in reduced-risk products. By 2023, IQOS had expanded to over 70 markets worldwide, with more than 20 million users globally. The product's name stands for "I Quit Ordinary Smoking," reflecting its positioning as an alternative for adult smokers who would otherwise continue using traditional cigarettes.

How It Works

IQOS operates on a fundamentally different principle than traditional cigarettes by heating rather than burning tobacco.

• Heating Technology: The IQOS device uses an electronically controlled heating blade that heats specially designed HEETS tobacco sticks to precisely 350°C (662°F). This temperature is significantly lower than the 600-900°C (1112-1652°F) combustion temperature of traditional cigarettes, preventing tobacco from burning and producing smoke.
• Tobacco Stick Design: HEETS sticks contain processed tobacco that's been compressed and treated specifically for heating. Each stick provides approximately 14 puffs or 6 minutes of use, similar to a traditional cigarette. The tobacco is wrapped in a special paper that facilitates even heating without combustion.
• Device Components: The IQOS system consists of three main components: the holder (which contains the heating blade), the pocket charger (which recharges the holder), and the HEETS tobacco sticks. The holder typically provides one session per charge, after which it must be returned to the pocket charger for approximately 90 seconds to recharge.
• Aerosol Generation: When heated, the tobacco releases nicotine and flavor in an aerosol that users inhale. PMI claims this aerosol contains approximately 90-95% lower levels of harmful chemicals compared to cigarette smoke, though it still contains nicotine, which is addictive.

Key Comparisons

Why It Matters

• Public Health Impact: With over 1 billion smokers worldwide according to WHO estimates, IQOS represents a potential harm reduction approach. PMI's research suggests switching completely to IQOS reduces exposure to harmful chemicals, though health authorities emphasize that no tobacco product is completely safe.
• Regulatory Evolution: IQOS has prompted significant regulatory discussions globally. In 2019, the U.S. FDA authorized IQOS for sale as a Modified Risk Tobacco Product (MRTP), marking the first time any tobacco product received such authorization. However, regulations vary significantly by country, with some nations banning heated tobacco products entirely.
• Market Transformation: The tobacco industry is undergoing its most significant transformation in decades. PMI has invested over $8 billion in smoke-free products since 2008 and aims for over 50% of its revenue to come from smoke-free products by 2025. IQOS generated approximately $9 billion in net revenues for PMI in 2022, representing about 30% of the company's total revenue.

The future of IQOS and similar products will depend on ongoing scientific research, regulatory developments, and consumer adoption patterns. As public health organizations continue to study the long-term effects of heated tobacco products, and as technology evolves with newer versions like IQOS ILUMA (which uses induction heating rather than a blade), the heated tobacco category represents both a business transformation for tobacco companies and a complex public health question. The ultimate impact will be measured not just in market share, but in whether these products genuinely contribute to reducing tobacco-related harm on a population level while preventing youth initiation and supporting complete cessation where possible.